RVX's core product RVX-208 has basically completed Phase II clinical study; it is about to enter Phase III clinical trail; RVX needs investment for the Phase III clinical trials, and it is willing to license the Chinese rights.
Shenzhen Hepalink is a Chinese listed pharmaceutical company with 20 billion RMB market capitalization; its main business is the research, development, manufacture and sales of heparin products.
Found an optimal deal structure that can meet the needs of both parties.
Assisted RVX understand the registration process required by CFDA, as well as the requirements of international multi-center clinical trial.
Helped RVX understand the pharmaceutical distribution process so that a proper licensing agreement can be reached.
BFC assisted RVX to look for partners in China, and efficiently completed the transaction within six months.
Hepalink led the CAD$50 million private placement, and subscribed $35 million common shares; Eastern Capital subscribed CAD$15 million common shares.
RVX has exclusively licensed the Chinese rights of RVX-208 to Hepalink in China, Hong Kong, Taiwan and Macau.